No data to show
XNAS
AKTX
Market cap6kUSD
Apr 02, Last price
1.10USD
1D
0.00%
1Q
-9.09%
Jan 2017
-99.22%
IPO
-99.93%
Name
Akari Therapeutics PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-20.90%
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L+43.54%
CFO
-16m
L-23.59%
Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 23,488 | 23,088 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (23,488) | (23,088) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (10,776) | ||||||||
Tax Rate | |||||||||
NOPAT | (23,488) | (12,312) | |||||||
Net income | (10,008) 43.54% | (6,972) -60.40% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 7,020 | 25,194 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 947 | ||||||||
Net debt | (3,845) | (13,250) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (16,432) | (21,505) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 7,020 | 25,288 | |||||||
FCF | (23,245) | (12,312) | |||||||
| Balance | |||||||||
Cash | 3,845 | 13,250 | |||||||
Long term investments | |||||||||
Excess cash | 3,845 | 13,250 | |||||||
Stockholders' equity | (174,983) | (217,479) | |||||||
Invested Capital | 174,754 | 219,270 | |||||||
ROIC | |||||||||
ROCE | 10,256.77% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 4,894 | 3,122 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (23,484) | (23,084) | |||||||
EV/EBITDA | |||||||||
Interest | 5,340 | ||||||||
Interest/NOPBT | |||||||||